Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Mol Cancer Ther. 2016 Nov 30;16(2):376–387. doi: 10.1158/1535-7163.MCT-16-0381

Figure 6. Dose linearity between the microdose and therapeutic dose in PDX xenograft model BL0645 and BL0293.

Figure 6

NSG mice were implanted with PDX model BL0645 14 days before microdosing. Animals were dose with A) 37.5 mg/kg carboplatin (50,000 dmp/g, red bar) or 37.5 mg/kg carboplatin (50,000 dpm/g) plus 9.2 mg/kg unlabeled gemcitabine (green bar), B) 9.2 mg/kg gemcitabine (1,000 dpm/g, red bar) or 9.2 mg/kg gemcitabine (1,000 dpm/g) plus 37.5 mg/kg unlabeled carboplatin (green bar). After 24h, DNA was isolated from collected tumor tissue and analyzed via AMS. C) Dose proportionality is shown by plotting microdose and therapeutic dose induced adduct level onto log scale. Student's t-test was used to measure all p values. Presented are means and error bars represent SEM.